Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
As the global HIV community gathers this week in Durban, South Africa for the International AIDS Conference, their focus should be on strengthening community-led responses, along […]
Findings highlight gaps in available testing, regimens The first survey to assess tuberculosis that does not respond to common treatments across populations in multiple high-disease-burden countries […]
While Ebola funds dwindle, a study to test treatment for persistent virus begins, and a report cites gaps in outbreak response capacities
The work of controlling, learning from deadliest Ebola outbreak, preparing for future continues, amid uncertain funding for ongoing responses to crisis A study of men who […]
In February, when the Obama Administration proposed a $1.9 billion package to respond to the Zika outbreak, Centers for Disease Control and Prevention Director Tom Frieden […]